

Post-operative analgesia for day-case ankle arthroscopy

Submission date 28/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/05/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 19/09/2016	Condition category Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Richard Venn

Contact details
Worthing and Southlands Hospitals
Anaesthetics Department
Lyndhurst Road
Worthing
West Sussex
United Kingdom
BN11 2DH

Additional identifiers

Protocol serial number
6718

Study information

Scientific Title
Post-operative analgesia for day-case ankle arthroscopy: comparison of intra-articular racemic (RS)-bupivacaine with S(-)-bupivacaine

Acronym

Bupivacaine study

Study objectives

1. To investigate whether intra-articular S(-)-bupivacaine provides prolonged duration of post-operative analgesia in comparison to racemic (RS)-bupivacaine following ankle arthroscopy
2. To investigate whether intra-articular S(-)-bupivacaine reduces supplemental analgesia requirements in comparison to racemic (RS)-bupivacaine following ankle arthroscopy

Ethics approval required

Old ethics approval format

Ethics approval(s)

Brighton East REC, 12/09/2007, ref: 07/Q1907/34

Study design

Multicentre randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Anaesthetics

Interventions

Post-operative, single injection of 20 ml of 0.5% S(-)-bupivacaine or 20 ml 0.5% racemic (RS)-bupivacaine into the ankle joint.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Bupivacaine

Primary outcome(s)

The analgesic effect of treatments:

1. Time to first supplemental analgesia following discharge from recovery
2. Visual Analogue Scale (VAS) at 30 mins, 1 hour

Key secondary outcome(s)

1. Differences in VAS scores between intra-articular chirocaine and marcaïn in the first 24 hours
2. Investigate whether intra-articular chirocaine reduces supplemental analgesia requirements in comparison to marcaïn in the first 24 hours

Completion date

01/11/2009

Eligibility

Key inclusion criteria

Patients aged 18 years and above undergoing day case ankle arthroscopy who have given informed written consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Allergy or intolerance to any drugs used in the study
2. Spinal or epidural anaesthesia
3. Pregnancy

Date of first enrolment

29/04/2008

Date of final enrolment

01/11/2009

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Worthing and Southlands Hospitals

West Sussex

United Kingdom

BN11 2DH

Sponsor information

Organisation

Sussex NHS Research Consortium (UK)

Funder(s)

Funder type

Industry

Funder Name

Abbott Laboratories Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes